SCHEMBL2697804

SCHEMBL2697804

COC(=O)C(F)c1ccc2ncccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.56
HTT P42858 1/20 0.56
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
ALDH1A1 P00352 3/20 0.49
PLK1 P53350 1/20 0.49
NPC1 O15118 4/20 0.48
POLB P06746 3/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
RAB9A P51151 3/20 0.46
MET P08581 3/20 0.46
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NR3C1 P04150 1/20 0.43
MCL1 Q07820 1/20 0.43
PABPC1 P11940 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19926091 0.86 ALOX15 (0.58) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL1669333 0.84 ALOX15 (0.57) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL14320091 0.82 AKR1C3 (0.53) ALOX15HTTALDH1A1PLK1NPC1
SCHEMBL2699086 0.82 AKR1C3 (0.53) ALOX15HTTALDH1A1PLK1NPC1
SCHEMBL19926229 0.82 ALOX15 (0.55) ALOX15HTTTAS1R3TAS1R1ALDH1A1
Hydrochloric Acid SCHEMBL3593418 0.81 AKR1C3 (0.52) ALOX15HTTALDH1A1PLK1NPC1
SCHEMBL3344555 0.81 ALOX15 (0.53) ALOX15HTTTAS1R3TAS1R1ALDH1A1
SCHEMBL27838268 0.81 MAPT (0.48) ALOX15HTTALDH1A1PLK1NPC1
Hydrochloric Acid SCHEMBL27838274 0.80 NPC1 (0.47) ALOX15HTTALDH1A1PLK1NPC1
SCHEMBL11467664 0.79 SLC6A3 (0.50) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 EP disclosed
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 EP disclosed
EP-2081931-B1 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor AMGEN INC (US) 2016-08-31 EP disclosed
EP-2081931-B1 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor AMGEN INC (US) 2016-08-31 EP disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 US disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 US disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 US disclosed
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-11-14 US disclosed
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-11-14 US disclosed
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-11-14 US disclosed
CN-101528743-A Fused heterocyclic derivatives and methods of use AMGEN INC (US) 2009-09-09 CN disclosed
EP-2081931-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen Inc. (US) 2009-07-29 EP disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 WO disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124612-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET ALOX15 1069/4885HTT 595/4885TAS1R3 4861/4885
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET ALOX15 1069/4885HTT 595/4885TAS1R3 4861/4885
US-20090124609-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET ALOX15 1069/4885HTT 595/4885TAS1R3 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.